CHANGE MY LOCATION
Business and Finance
Business News
- National Intelligence Director Mike McConnell says the terrorist group U.S. intelligence believes carried out last week's attack in Mumbai is the same one that attacked Mumbai trains in 2006.
Ga. Senate runoff could decide balance of power- Georgia's seemingly endless U.S. Senate campaign drew to a finish on Tuesday as polls closed on the hotly-contested race that will sway the balance of power in Washington.
Auditors fault Treasury oversight of bailout funds- The government must toughen its monitoring of the $700 billion financial bailout to ensure that banking institutions limit their top executives' pay and comply with other restrictions, federal auditors said Tuesday in the first comprehensive review of the rescue package.
Gates: Military looks to accelerate Iraq pullout- Defense Secretary Robert Gates signaled a willingness Tuesday to forge ahead with two key priorities for the incoming Obama administration: accelerating the U.S. withdrawal from Iraq and shutting down the Guantanamo Bay detention center.
Nixon records show aides dishing dirt on critics- In Richard Nixon's time, all the president's men fretted about threats on every front: disquiet out on the streets, disloyalty inside the administration and trouble from political opponents who had to be discredited at any cost.
Chained teen shows up at Calif. gym; 2 arrested- A Girl Scout leader and her husband were arrested after an emaciated, terrified and nearly naked 17-year-old showed up at a gym with a chain locked to his ankle, saying he had just fled his captors, authorities said Tuesday.
Hudson in-law charged with killing 3 relatives- Jennifer Hudson's brother-in-law was charged with murder Tuesday in the shooting deaths of three of the actress's family members, including the 7-year-old son of his estranged wife.
Coleman pleads no contest to disorderly conduct- Gary Coleman has pleaded no contest to a disorderly conduct charge stemming from a September incident at a bowling alley. The 40-year-old former star of "Diff'rent Strokes" was ordered to pay a $100 fine in a Payson court Tuesday. He also pleaded no contest to a reckless driving charge, which will be waived if he doesn't have any other violations within a year.
- A message in a bottle tossed into the ocean off Barnegat Bay has turned up in North Carolina - 39 years later. The note was sealed in a Schaefer beer bottle. It was dated Aug. 17, 1969 and read: "If found notify the North Haledon Fire Co. 2."
Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
SAN FRANCISCO
(Map)
-
Of the patients enrolled in this study, a sub-group of 276 patients were identified as having type 2 diabetes. Data from this sub-group demonstrated that the comprehensive effect of TriLipix in combination with rosuvastatin was similar to that seen in the overall study population. Compared to corresponding monotherapies, patients receiving TriLipix in combination with rosuvastatin had significant decreases in triglycerides and LDL, in addition to clinically meaningful improvements in HDL.
Dyslipidemia affects millions of Americans living with diabetes. These patients often have mixed dyslipidemia, a complex combination of lipid problems commonly characterized by high triglycerides, low HDL and moderately high LDL.
"Treatment guidelines recommend aggressive treatment of lipids in patients
with mixed dyslipidemia and type 2 diabetes," said
About the Study
This 12-week, multi-center, double blind, controlled Phase III study of 1,400 patients evaluated the efficacy and safety of TriLipix in combination with rosuvastatin on multiple lipid parameters. Patients enrolled in the study had multiple lipid problems, with baseline LDL greater than or equal to 130 mg/dL, HDL less than 40 mg/dL for males and less than 50 mg/dL for females and triglycerides greater than or equal to 150 mg/dL.
Patients were randomized to receive TriLipix (135mg) combined with either 10mg or 20mg of rosuvastatin, TriLipix alone (135mg) or rosuvastatin alone (10mg, 20mg or 40mg). The 40mg rosuvastatin arm was included in the study to assess safety and adverse events, but was not included in the statistical analysis.
The primary comparisons were mean percent change in HDL and triglycerides for TriLipix combined with rosuvastatin compared to rosuvastatin alone, and mean percent change in LDL for TriLipix combined with rosuvastatin compared to TriLipix alone. The combination of TriLipix and rosuvastatin significantly improved LDL compared to TriLipix alone, and significantly improved HDL and triglycerides compared to rosuvastatin alone.
A total of 276 patients included in the primary efficacy analysis had type 2 diabetes and were included in a sub-group analysis. Diabetic patients treated with the combination of TriLipix 135mg and rosuvastatin 10mg had an increase in HDL of 21.0 percent and decrease in triglycerides of 44.7 percent compared to an HDL increase of 6.6 percent and triglyceride decrease of 28.8 percent with rosuvastatin 10mg alone. LDL decreased 37.1 percent with the combination compared to 6.1 percent with TriLipix 135mg monotherapy.
Patients treated with the combination of TriLipix 135mg and rosuvastatin 20mg had an increase in HDL of 17.6 percent and decrease in triglycerides of 42.4 percent compared to an HDL increase of 12.2 percent and triglyceride decrease of 26.8 percent with rosuvastatin 20mg alone. LDL decreased 37.4 percent with the combination compared to 6.1 percent with TriLipix 135mg monotherapy.
"New treatment options are critical given that a substantial number of
patients are not achieving treatment goals for their three key lipids," said
About the TriLipix Clinical Trial Program
The efficacy and safety of TriLipix in combination with the three most commonly prescribed statins -- rosuvastatin, atorvastatin and simvastatin -- were evaluated in three randomized, multi-center, double-blind, controlled, 12-week Phase III studies, totaling 2,698 patients with mixed dyslipidemia.
These studies, along with a 52-week long-term safety and efficacy open-label extension study of 1,911 patients, represent the largest program to date examining a fibrate in combination with statins. More than 2,200 patients were treated with TriLipix alone and in combination with statins across these four studies.
The primary data for TriLipix combined with statins were presented at scientific forums earlier this year.
About TriLipix (ABT-335)
TriLipix is an investigational new fenofibric acid molecule, currently in
clinical development for treating patients with unhealthy lipid levels,
including LDL cholesterol, triglycerides and HDL cholesterol. A New Drug
Application (NDA) for TriLipix for use as monotherapy and in combination with
statins has been submitted to the U.S. Food and Drug Administration (FDA).
About
SOURCE
|
|
More Business_and_Finance Releases
(BBBY): Bed Bath & Beyond Inc. Presently Estimates Net Earnings of Approximately $.31 to $.35 Per Diluted Share for Fiscal Third Quarter Ended November 29, 2008
(LMT): Lockheed Martin Selected for Contract by NASA for Next Generation GOES-R Series Weather Satellites
(NSANY): 2009 Infiniti G Line Named to '10 Best Cars' List by Car and Driver Magazine
(WFMI): Whole Foods Market Announces Four New Members to Its Board of Directors
